Aluminum Hydroxide Magnesium Carbonate Sodium Bica

證據等級: L5

預測適應症: 0 個

Aluminum Hydroxide / Magnesium Carbonate / Sodium Bicarbonate: Antacid Combination — No Repurposing Candidates Identified

One-Sentence Summary

Aluminum Hydroxide / Magnesium Carbonate / Sodium Bicarbonate is a classic triple-component antacid combination, widely used in clinical practice to neutralize gastric acid and relieve symptoms of heartburn, acid indigestion, and peptic ulcers. The TxGNN model did not generate any repurposing predictions for this drug combination, likely because the combination product lacks a DrugBank ID mapping required for knowledge graph traversal. As a result, no clinical trial or literature evidence for a new indication can be presented at this time.

Quick Overview

Item	Content
Original Indication	Gastric acid neutralization (heartburn, acid indigestion, peptic ulcer)
Predicted New Indication	None identified
TxGNN Prediction Score	N/A — no prediction generated
Evidence Level	N/A
Taiwan Market Status	✗ Not marketed (0 approved licenses)
Number of Licenses	0
Recommended Decision	Hold

Why No Prediction Was Generated

This combination product — aluminum hydroxide, magnesium carbonate, and sodium bicarbonate — functions as a buffering antacid through complementary mechanisms:

Aluminum hydroxide reacts with hydrochloric acid to form aluminum chloride and water, additionally binding dietary phosphate in the gastrointestinal tract.
Magnesium carbonate neutralizes gastric acid and provides a mild laxative effect that counterbalances the constipating tendency of aluminum hydroxide.
Sodium bicarbonate acts as a rapid-onset alkalinizing agent, providing immediate symptom relief.

Despite the DrugBank query returning one result, the drug record could not be resolved to a DrugBank ID (drugbank_id: null). Without a valid DrugBank ID, the TxGNN knowledge graph pipeline cannot traverse drug–disease relationships, and no repurposing predictions are generated. This is a pipeline mapping failure rather than a clinical negative finding — it does not mean this combination has no repurposing potential.

Additionally, this drug combination is not currently marketed in Taiwan (0 TFDA approvals), which further limits regulatory and clinical context.

Clinical Trial Evidence

Currently no related clinical trials registered.

(No predicted indication available; clinical trial retrieval requires a TxGNN-predicted target disease.)

Literature Evidence

Currently no related literature available.

(No predicted indication available; literature retrieval requires a TxGNN-predicted target disease.)

Taiwan Market Information

This drug combination has no approved licenses in Taiwan and is classified as not marketed (未上市). No product records were returned from the TFDA query.

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug interaction data are unavailable for this submission. DrugBank MOA data was also not resolved due to missing DrugBank ID.)

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model could not process this drug combination because the multi-component product lacks a resolvable DrugBank ID, making knowledge graph traversal impossible. Without a predicted indication, repurposing evaluation cannot proceed. This is a data pipeline issue rather than a clinical verdict.

To proceed, the following is needed:

Resolve DrugBank mapping: Query DrugBank for each individual active ingredient separately (DB01122 for aluminum hydroxide, DB09481 for magnesium carbonate, DB01390 for sodium bicarbonate) and run TxGNN predictions on each component independently.
Re-run pipeline per component: Disaggregate the combination and execute KG + DL predictions for each INN individually, then consolidate results.
Retrieve MOA data: Pull mechanism of action descriptions for each component from DrugBank API to enable mechanistic plausibility scoring.
Taiwan regulatory review: Confirm whether any single-ingredient or alternative combination formulations of these antacid components are approved in Taiwan, as this may clarify the regulatory pathway.
Safety data remediation: Download and parse TFDA package insert PDF (DG001) to complete the safety profile before any S1 evaluation.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.